Altium Capital Management »

Skye Bioscience shares owned by Altium Capital Management

Quarter-by-quarter ownership of Skye Bioscience (SKYE) shares owned by Altium Capital Management from 13F filings

Historical chart of Altium Capital Management investment in Skye Bioscience

Tip: Access up to 7 years of quarterly data

All positions including Skye Bioscience held by Altium Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Skye Bioscience by Altium Capital Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $11M 1.4M 8.01

More positions owned by Altium Capital Management

Vera Therapeutics Cl A (VERA)
Adma Biologics (ADMA)
Xenon Pharmaceuticals (XENE)
Intra Cellular Therapies (ITCI)
Sarepta Therapeutics (SRPT)
Insmed Com Par $.01 (INSM)
Alimera Sciences Com New
Skye Bioscience Com New (SKYE)
Argenx Se Sponsored Adr (ARGX)
Soleno Therapeutics (SLNO)
Avadel Pharmaceuticals Com Shs (AVDL)
Catalyst Pharmaceutical Partners (CPRX)
Contineum Therapeutics Cl A (CTNM)
Rezolute Com New (RZLT)
Ascendis Pharma A/s Sponsored Adr (ASND)

View all positions for Altium Capital Management

Top funds holding Skye Bioscience

5AM Venture Management
Versant Venture Management
Baker Bros. Advisors
Altium Capital Management
Logos Global Management
Sphera Funds Management
BlackRock
BlackRock
Schonfeld Strategic Advisors
Henderson Group
Ensign Peak Advisors
Vanguard Group
CVI Holdings
Driehaus Capital Management
Alyeska Investment Group

View all funds holding Skye Bioscience